בשל "הגנת זכויות יוצרים", מובא להלן קישור למאמר בלבד. לקריאתו בטקסט מלא, אנא פנה לספרייה הרפואית הזמינה לך.
The use of spectral-domain optical coherence tomography (OCT) has revolutionized the management of diabetic macular edema (DME), because it has emerged as a quick and noninvasive method of determining response to treatment and need for additional treatment based on resolution of fluid and changes in retinal thickness.
The presumption is that OCT morphological findings are a meaningful indicator of visual function.
In this issue of JAMA Ophthalmology, the DRCR Retina Network1 assessed the association between changes in OCT central subfield thickness (CST) and visual acuity (VA) by analyzing pooled data from protocol T, which randomized eyes with center-involved DME to 1 of 3 anti–vascular endothelial growth factor (anti-VEGF) agents: bevacizumab, ranibizumab, or aflibercept.